Crossmark

Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies

Crossref DOI link: https://doi.org/10.1038/s41409-021-01217-w

Published Online: 2021-03-03

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shimomura, Yoshimitsu https://orcid.org/0000-0003-1018-9508
Hara, Masahiko

Yamamoto, Hisashi

Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Kawakita, Toshiro

Ashida, Takashi

Takada, Satoru

Ikeda, Takashi https://orcid.org/0000-0003-3976-5230
Morishige, Satoshi

Maruyama, Yumiko https://orcid.org/0000-0003-1410-0830
Wake, Atsushi

Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Fukuda, Takahiro

Takanashi, Minoko

Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Ishikawa, Takayuki
License Information

Text and Data Mining valid from 2021-03-03

Version of Record valid from 2021-03-03
More Information

Article History

Received: 22 June 2020

Revised: 21 December 2020

Accepted: 8 January 2021

First Online: 3 March 2021

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below